title: [A comparison of intra-arterial chemoembolization and infusion chemotherapy for liver metastases of breast cancer].
abstract: Seventeen patients with liver metastases of breast cancer were treated with a combination of intra-arterial chemotherapy and endocrine therapy at our hospital from 1986 to 1994. Of 17 patients, 9 were treated with transarterial chemoembolization through hepatic artery using 40-50 mg/body of 4'epi-adriamycin (epi-ADM) and lipiodol, and the other 8 were treated with hepatic infusion chemotherapy using 20-30 mg/body of epi-ADM every 2 weeks. All patients were followed by endocrine therapy with oral administration of 800-1,200 mg/day of medroxyprogesterone acetate (MPA). The results were as follows: 1) The comparison of response rate between the two groups was not substantially changed (44.4% x 4/9 in TAE group and 50.0% x 4/8 in Reservoir group). 2) Duration of response was 4-45 months (mean 25 months) in TAE group and 3-15+ alpha months (mean 8.7 months) in Reservoir group. But in the latter group, 3 patients are now under treatment. 3) At one year, the survival rates were 44.4 percent in TAE group and 50.0 percent in Reservoir group. We conclude that combination of intra-arterial chemotherapy and endocrine therapy is a useful treatment modality for controlling liver metastases of breast cancer.
authors.affiliation: Dept. of Surgery, Osaka Teishin Hospital.
authors.forename: E
authors.initials: E
authors.lastname: Yayoi
authors.forename: J
authors.initials: J
authors.lastname: Furukawa
authors.forename: M
authors.initials: M
authors.lastname: Sekimoto
authors.forename: M
authors.initials: M
authors.lastname: Kinuta
authors.forename: H
authors.initials: H
authors.lastname: Tateishi
authors.forename: H
authors.initials: H
authors.lastname: Maruyama
authors.forename: J
authors.initials: J
authors.lastname: Okamura
authors.forename: H
authors.initials: H
authors.lastname: Ooi
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000473:pathology*; D016461:Chemoembolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007231:Infant, Newborn; D015918:Infusion Pumps, Implantable; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D015251:Epirubicin; D007459:Iodized Oil; D017258:Medroxyprogesterone Acetate